Valan Bruno, Anastasio Albert T, Kim Billy, Krez Alexandra, Wu Kevin A, Talaski Grayson M, Nunley James, DeOrio James K, Easley Mark E, Adams Samuel B
Division of Foot and Ankle, Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Department of Orthopaedic Surgery, Hospital for Special Surgery, New York City, NY 10021, USA.
Diagnostics (Basel). 2024 Jul 26;14(15):1612. doi: 10.3390/diagnostics14151612.
Launched in 2018 for revision total ankle arthroplasty (rTAA), the INVISION talar component addresses subsidence when poor talar bone stock is present. Due to the recency of the market-availability of the INVISION, studies evaluating its efficacy are lacking. This study presents the first analysis of early-term outcomes of patients undergoing rTAA with the INVISION talar component.
This was a single-center, retrospective review of 28 patients undergoing rTAA with the INVISION talar component and INBONE II tibial component performed between 2018 and 2022. Data on preoperative characteristics, postoperative complications, secondary procedures, and survivorship were collected. The primary outcome measures were rates of major complications, re-operation, and implant failure. Secondary outcomes included post-operative changes in varus and valgus alignment of the tibia and talus.
The most common secondary procedures performed with rTAA were medial malleolus fixation ( = 22, 78.6%) and gastrocnemius recession ( = 14, 50%). Overall, 10.7% ( = 3) of patients underwent reoperation and 14.3% ( = 4) suffered major complications. Incidence of implant failure was 10.7% ( = 3). All reoperations were caused by infection. Mean varus alignment of the tibia and talus improved from 4.07 degrees and 4.83 degrees to 1.67 degrees and 1.23 degrees, respectively. Mean valgus alignment of the tibia and talus improved from 3.67 degrees and 4.22 degrees to 2.00 degrees and 2.32 degrees, respectively.
In a series of 28 patients undergoing rTAA with the INVISION talar component, we discovered comparatively low rates of reoperation, major complication, and implant failure (10.7%, 14.3%, and 10.7%). The INVISION system appears to have a reasonable safety profile, but further studies evaluating long-term outcomes are required to assess the efficacy of the INVISION system.
INVISION距骨组件于2018年推出，用于翻修全踝关节置换术（rTAA），当距骨骨量不佳时可解决下沉问题。由于INVISION在市场上可用的时间较短，缺乏评估其疗效的研究。本研究首次分析了使用INVISION距骨组件进行rTAA患者的早期结局。
这是一项单中心回顾性研究，对2018年至2022年间接受INVISION距骨组件和INBONE II胫骨组件rTAA的28例患者进行了研究。收集了术前特征、术后并发症、二次手术和生存率的数据。主要结局指标为主要并发症、再次手术和植入物失败的发生率。次要结局包括胫骨和距骨内翻和外翻对线的术后变化。
rTAA最常见的二次手术是内踝固定（n = 22，78.6%）和腓肠肌松解（n = 14，50%）。总体而言，10.7%（n = 3）的患者接受了再次手术，14.3%（n = 4）发生了主要并发症。植入物失败的发生率为10.7%（n = 3）。所有再次手术均由感染引起。胫骨和距骨的平均内翻对线分别从4.07度和4.83度改善至1.67度和1.23度。胫骨和距骨的平均外翻对线分别从3.67度和4.22度改善至2.00度和2.32度。
在一系列28例使用INVISION距骨组件进行rTAA的患者中，我们发现再次手术、主要并发症和植入物失败的发生率相对较低（分别为10.7%、14.3%和10.7%）。INVISION系统似乎具有合理的安全性，但需要进一步评估长期结局的研究来评估INVISION系统的疗效。
